← Leaderboards
David J Greenblatt
Tufts Medical Center
$6,267,969
Attributed
$6,267,969
Total exposure
11
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $818.6K · FY2005–06$1M$750K$500K$250K$0
'05
'06
Funding mix
By agency
NIH$6,267,969 · 11
By mechanism
R01$5,307,190 · 5
R21$746,250 · 2
P41$149,975 · 2
M01$64,554 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectCytochrome P450PharmacokineticsAids TherapyTissue /Cell CultureMidazolamDrug InteractionsRitonavirAntiviral AgentsDrug MetabolismP GlycoproteinClearance RateHiv InfectionsWestern BlottingsAge DifferenceGlutamate ReceptorGene ExpressionHistochemistry /CytochemistryProtein IsoformsStimulant /AgonistAntiaids AgentDrug Adverse EffectCombination Chemotherapy
Grant awards (30)
CYP3A Function in Aging AfricanAmericans$232,163
R01 · FY2006 · AG · contact PI
CHRONIC BENZODIAZEPINES: BEHAVIOR AND NEUROCHEMISTRY$279,197
R01 · FY2005 · DA
MDR1 and Related Proteins during HIV PI Exposure$245,250
R21 · FY2005 · AI
CYP3A Function in Aging AfricanAmericans$237,750
R01 · FY2005 · AG
COLLABORATORY EXTENSION TO CHIMERA$56,419
P41 · FY2005 · RR
GARLIC PREPARATIONS AND ANTIRETROVIRAL DRUGS$356,625
R01 · FY2004 · AT
CHRONIC BENZODIAZEPINES: BEHAVIOR AND NEUROCHEMISTRY$282,053
R01 · FY2004 · DA
CYP3A Function in Aging AfricanAmericans$237,750
R01 · FY2004 · AG
COLLABORATORY EXTENSION TO CHIMERA$93,556
P41 · FY2004 · RR
CX516 (Ampalex) in Healthy Elderly Males and Females$21,815
M01 · FY2004 · RR
GARLIC PREPARATIONS AND ANTIRETROVIRAL DRUGS$356,625
R01 · FY2003 · AT
CHRONIC BENZODIAZEPINES: BEHAVIOR AND NEUROCHEMISTRY$281,905
R01 · FY2003 · DA
HAART Regimens in Substance Abusers$277,375
R01 · FY2003 · DA
Metabolic Consequences of HAART: CYP3A and P-gp$263,506
R01 · FY2003 · DK
CYP3A Function in Aging AfricanAmericans$237,750
R01 · FY2003 · AG
GARLIC PREPARATIONS AND ANTIRETROVIRAL DRUGS$356,625
R01 · FY2002 · AT
CHRONIC BENZODIAZEPINES: BEHAVIOR AND NEUROCHEMISTRY$281,755
R01 · FY2002 · DA
HAART Regimens in Substance Abusers$277,375
R01 · FY2002 · DA
Metabolic Consequences of HAART: CYP3A and P-gp$263,506
R01 · FY2002 · DK
CYP3A Function in Aging AfricanAmericans$237,750
R01 · FY2002 · AG
ANTIRETROVIRAL THERAPIES AND SUBSTANCE ABUSE$167,000
R21 · FY2002 · DA
INTERACTION AMITRIPTYLINE WITH KETOCONAZOLE AND QUINIDINE$0
M01 · FY2002 · RR
HAART Regimens in Substance Abusers$277,375
R01 · FY2001 · DA
Metabolic Consequences of HAART: CYP3A and P-gp$263,506
R01 · FY2001 · DK
CHRONIC BENZODIAZEPINES: BEHAVIOR AND NEUROCHEMISTRY$262,750
R01 · FY2001 · DA
ANTIRETROVIRAL THERAPIES AND SUBSTANCE ABUSE$167,000
R21 · FY2001 · DA
CHRONIC BENZODIAZEPINES: BEHAVIOR AND NEUROCHEMISTRY$43,849
R01 · FY2001 · DA
INTERACTION AMITRIPTYLINE WITH KETOCONAZOLE AND QUINIDINE$0
M01 · FY2001 · RR
ANTIRETROVIRAL THERAPIES AND SUBSTANCE ABUSE$167,000
R21 · FY2000 · DA
INTERACTION AMITRIPTYLINE WITH KETOCONAZOLE AND QUINIDINE$42,739
M01 · FY2000 · RR